“…It is pointed out by heads of state and the WHO that universal health coverage (UHC, Good Health and Well-being) as described in Sustainable Development Goal 3.8 (SDGs) cannot be achieved without ensuring the quality of medicines. In many countries, especially low- and middle-income countries (LMICs), medicine regulation authorities, manufacturers, and researchers are struggling to prevent the distribution of SFMs ( Lon et al, 2006 , Amin and Kokwaro, 2007 , Gaudiano et al, 2007 , Khan et al, 2010 , Khan et al, 2011a , Khan et al, 2011b , Binagwaho et al, 2013 , Yoshida et al, 2014 , Otte et al, 2015 , Petersen et al, 2017 , Yong et al, 2015 , Kakio et al, 2017 , Khuluza et al, 2017 , Kakio et al, 2018 , Pisani et al, 2019 , Tabernero et al, 2019 , Schäfermann et al, 2020 ). However, the prevalence of SFMs is currently increasing globally, especially in LMICs, where the proportion of SFMs has reached 10.5% of the pharmaceutical market ( WHO, 2018 ).…”